Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers
DESTINY-Brest03 was a prospective randomized phase 3 clinical trial that aimed to compare the efficacy of trastuzumab deruxtecan (T-DXd) with that of trastuzumab emtansine (T-DM1) in patients suffering from HER2 positive metastatic breast cancers.